TrialAmerican journal of clinical dermatology2020

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.

Lisa A Beck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.